|
1
|
Kim ES, Khuri FR and Herbst RS: Epidermal
growth factor receptor biology (IMC-C225). Curr Opin Oncol.
13:506–513. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Woodburn JR: The epidermal growth factor
receptor and its inhibition in cancer therapy. Pharmacol Ther.
82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galizia G, Lieto E, De Vita F, Orditura M,
Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab,
a chimeric human mouse anti-epidermal growth factor receptor
monoclonal antibody, in the treatment of human colorectal cancer.
Oncogene. 26:3654–3660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harris M: Monoclonal antibodies as
therapeutic agents for cancer. Lancet Oncol. 5:292–302. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chetty R and Govender D: Gene of the
month: KRAS. J Clin Pathol. 66:548–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao B, Wang L, Qiu H, Zhang M, Sun L,
Peng P, Yu Q and Yuan X: Mechanisms of resistance to anti-EGFR
therapy in colorectal cancer. Oncotarget. 8:3980–4000.
2017.PubMed/NCBI
|
|
7
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pessino A, Artale S, Sciallero S,
Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D,
Caprioni F, Bennicelli E, et al: First-line single-agent cetuximab
in patients with advanced colorectal cancer. Ann Oncol. 19:711–716.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Geva R, Vecchione L, Kalogeras KT, Jensen
BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo
F, et al: FCGR polymorphisms and cetuximab efficacy in
chemorefractory metastatic colorectal cancer: An international
consortium study. Gut. 64:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu G, Tu D, Lewis M, Cheng D, Sullivan
LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, et al: Fc-γ
receptor polymorphisms, cetuximab therapy, and survival in the NCIC
CTG CO.17 trial of colorectal cancer. Clin Cancer Res.
22:2435–2444. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weiner LM, Surana R and Wang S: Monoclonal
antibodies: Versatile platforms for cancer immunotherapy. Nat Rev
Immunol. 10:317–327. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Sorge NM, van der Pol WL and van de
Winkel JG: FcgammaR polymorphisms: Implications for function,
disease susceptibility and immunotherapy. Tissue Antigens.
61:189–202. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koene HR, Kleijer M, Algra J, Roos D, von
dem Borne AE and de Haas M: Fc gammaRIIIa-158V/F polymorphism
influences the binding of IgG by natural killer cell Fc gammaRIIIa,
independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood.
90:1109–1114. 1997.PubMed/NCBI
|
|
14
|
Dall'Ozzo S, Tartas S, Paintaud G, Cartron
G, Colombat P, Bardos P, Watier H and Thibault G:
Rituximab-dependent cytotoxicity by natural killer cells: Influence
of FCGR3A polymorphism on the concentration-effect relationship.
Cancer Res. 64:4664–4669. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Binstadt BA, Geha RS and Bonilla FA: IgG
Fc receptor polymorphisms in human disease: Implications for
intravenous immunoglobulin therapy. J Allergy Clin Immunol.
111:697–703. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amador ML, Oppenheimer D, Perea S, Maitra
A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C,
Forastiere A and Hidalgo M: An epidermal growth factor receptor
intron 1 polymorphism mediates response to epidermal growth factor
receptor inhibitors. Cancer Res. 64:9139–9143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buerger H, Gebhardt F, Schmidt H, Beckmann
A, Hutmacher K, Simon R, Lelle R, Boecker W and Brandt B: Length
and loss of heterozygosity of an intron 1 polymorphic sequence of
egfr is related to cytogenetic alterations and epithelial growth
factor receptor expression. Cancer Res. 60:854–857. 2000.PubMed/NCBI
|
|
18
|
Hsieh YY, Tzeng CH, Chen MH, Chen PM and
Wang WS: Epidermal growth factor receptor R521K polymorphism shows
favorable outcomes in KRAS wild-type colorectal cancer patients
treated with cetuximab-based chemotherapy. Cancer Sci. 103:791–796.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gonçalves A, Esteyries S, Taylor-Smedra B,
Lagarde A, Ayadi M, Monges G, Bertucci F, Esterni B, Delpero JR,
Turrini O, et al: A polymorphism of EGFR extracellular domain is
associated with progression free-survival in metastatic colorectal
cancer patients receiving cetuximab-based treatment. BMC Cancer.
8:1692008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soda H, Maeda H, Hasegawa J, Takahashi T,
Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, et
al: Multicenter phase II study of FOLFOX or biweekly XELOX and
Erbitux (cetuximab) as first-line therapy in patients with
wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
BMC Cancer. 15:6952015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hazama S, Maeda H, Iwamoto S, Kim HM,
Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K and Mishima H:
A phase II study of XELOX and cetuximab as first-line therapy in
patients with KRAS wild type metastatic colorectal cancer (FLEET2
Study). Clin Colorectal Cancer. 15:329–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inoue Y, Hazama S, Iwamoto S, Miyake Y,
Matsuda C, Tsunedomi R, Okayama N, Hinoda Y, Yamasaki T, Suehiro Y,
et al: FcγR and EGFR polymorphisms as predictive markers of
cetuximab efficacy in metastatic colorectal cancer. Mol Diagn Ther.
18:541–548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okayama N, Nishioka M, Hazama S, Sakai K,
Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, et
al: The importance of evaluation of DNA amplificability in KRAS
mutation testing with dideoxy sequencing using formalin-fixed and
paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol.
41:165–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maruta Y, Okayama N, Hiura M, Suehiro Y,
Hirai H and Hinoda Y: Determination of ancestral allele for
possible human cancerassociated polymorphisms. Cancer Genet
Cytogenet. 180:24–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pander J, Gelderblom H, Antonini NF, Tol
J, van Krieken JH, van der Straaten T, Punt CJ and Guchelaar HJ:
Correlation of FCGR3A and EGFR germline polymorphisms with the
efficacy of cetuximab in KRAS wild-type metastatic colorectal
cancer. Eur J Cancer. 46:1829–1834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kjersem JB, Skovlund E, Ikdahl T, Guren T,
Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM and Kure
EH: FCGR2A and FCGR3A polymorphisms and clinical outcome in
metastatic colorectal cancer patients treated with first-line
5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC
Cancer. 14:3402014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park SJ, Hong YS, Lee JL, Ryu MH, Chang
HM, Kim KP, Ahn YC, Na YS, Jin DH, Yu CS, et al: Genetic
polymorphisms of FcγRIIa and FcγRIIIa are not predictive of
clinical outcomes after cetuximab plus irinotecan chemotherapy in
patients with metastatic colorectal cancer. Oncology. 82:83–89.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Braig F, Kriegs M, Voigtlaender M, Habel
B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla
I, et al: Cetuximab Resistance in Head and Neck Cancer Is Mediated
by EGFR-K521 Polymorphism. Cancer Res. 77:1188–1199. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kobayashi M, Hazama S, Takahashi K, Oba K,
Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, et al:
Is there diversity among UGT1A1 polymorphism in Japan? World J
Gastrointest Oncol. 4:170–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. 3:194–201. 2017. View Article : Google Scholar : PubMed/NCBI
|
